Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlexanox for Obese Type 2 Diabetes
NCT01975935Phase 2Completed
- Sponsor
- University of Michigan
- Start
- Jan 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amlexanox in type 2 diabetes mellitus (T2DM), obesity, non-alcoholic fatty liver disease (NAFLD), sponsored by University of Michigan. Started Jan 2014; status: completed.
02
Drugs
amlexanox
03
Conditions
type 2 diabetes mellitus (T2DM)obesitynon-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT01975935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01975935.